



MILLIONS OF WOMEN MAY HAVE PAINFUL SEX DUE TO MENOPAUSE¹

But Many of Them May Not Be Receiving Treatment

**Learn About an Innovative Treatment for Moderate
to Severe Dyspareunia Due to Menopause²**

INTRAROSA® (prasterone) vaginal inserts for Moderate to Severe Dyspareunia,
A Symptom of Vulvar and Vaginal Atrophy (VVA), Due to Menopause²

INDICATION²

INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

IMPORTANT SAFETY INFORMATION²

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥ 2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥ 2 percent were vaginal discharge and abnormal Pap smear.

This program is sponsored by AMAG Pharmaceuticals, Inc.

Please also see accompanying full Prescribing Information.





DYSPAREUNIA DUE TO MENOPAUSE Is a Common but Undertreated Condition^{1,3,4}

There are an estimated 64 million postmenopausal women in the United States. About **HALF OF THEM** may suffer from symptoms of VVA, including dyspareunia.¹ This program provides insights on treating this underserved patient population.

PROGRAM OBJECTIVES

- Recognize the importance of initiating conversations about dyspareunia due to menopause with postmenopausal patients
- Introduce intravaginal prasterone, an inactive steroid, and its conversion into androgens and/or estrogens
- Review the clinical trial data on the efficacy, safety, and pharmacokinetic profile of INTRAROSA for the treatment of moderate to severe dyspareunia due to menopause
- Discuss the dosing and administration of INTRAROSA

The intended audience for this program is healthcare professionals involved in the treatment of postmenopausal women.

Friday, October 12, 2018 at 6:30AM

LOCATION

DoubleTree by Hilton Hotel Portland
1000 NE Multnomah Street
Portland, OR 97232

RSVP

<https://pharmethodportal.com/AMAG/register>
Meeting ID: **14108** or
Emmalyn Tribou at 503/875-6393.

FEATURED SPEAKER

Amber Masse, FNP-C
Family Nurse Practitioner, Rosemark
WomenCare Specialists

The speaker is contracted to speak on behalf of AMAG Pharmaceuticals, Inc.

Please also see accompanying full Prescribing Information.

1. Wysocki S, et al. *Clin Med Insights Reprod Health*. 2014;8:23-30. 2. INTRAROSA® (prasterone) Prescribing Information. AMAG Pharmaceuticals, Inc; 2018. 3. Cagnacci A, et al. *Menopause*. 2016;23(10):1139-1145. 4. Kingsberg SA, et al. *J Sex Med*. 2017;14(3):413-424.

This presentation is sponsored by AMAG Pharmaceuticals, Inc. ("AMAG"). In accordance with state regulations, healthcare professionals licensed in Minnesota and Vermont will not be provided food and/or beverage. AMAG will report and publicly disclose the costs associated with any meal provided to healthcare professionals as required by the applicable federal and state laws.